ProALLBL blood predictive lab test is being clinically developed for frequent and long-term monitoring of acute lymphoblastic leuekemia patients. Findings reported at the 2016 58th ASH Conference in San Diego show that ProALLBL miRNA levels correlate with ProALLBM miRNA levels in bone marrow. ProALLBL significantly predicted relapse of ALL patients.
Curewize is now performing the Clinical Trial "Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk" for the development of ProALLBL blood test.
Detect ALL molecular relapse before clinical Relapse.
Increase ALL relapse patients chances for survival
Improve ALL patients Quality of Life
ProALLBL test is planned to be available at the end of 2020.